SCHEMBL29954297

SCHEMBL29954297

Cc1ccc(C(=O)O)nc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 11/20 0.59
P4HA1 P13674 1/20 0.59
MIF P14174 1/20 0.59
KDM4E B2RXH2 4/20 0.57
ALDH1A1 P00352 3/20 0.57
L3MBTL1 Q9Y468 4/20 0.53
MAPK1 P28482 1/20 0.53
MAPT P10636 2/20 0.50
KMT2A Q03164 2/20 0.50
HIF1A Q16665 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
LMNA P02545 2/20 0.50
MEN1 O00255 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
PKM P14618 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
NFKB1 P19838 1/20 0.50
THPO P40225 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL82620 1.00 P4HTM (0.59) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL3997737 0.98 P4HTM (0.57) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL3997731 0.98 P4HTM (0.57) P4HTMP4HA1MIFKDM4EALDH1A1
Hydrochloric Acid SCHEMBL5955817 0.98 P4HTM (0.57) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL2270351 0.98 P4HTM (0.57) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL10328698 0.85 P4HTM (0.53) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL2633139 0.84 EGLN1 (0.62) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL827893 0.82 RAB9A (0.48) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL171039 0.80 KMT2A (0.53) P4HTMKDM4EALDH1A1MAPTKMT2A
SCHEMBL9179830 0.80 RAB9A (0.47) P4HTMP4HA1MIFKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025124460-A1 TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR, AND PREPARATION AND USE THEREFOR 石家庄以岭药业股份有限公司 2025-06-19 WO disclosed
EP-4463452-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2024-11-20 EP disclosed
US-20240368150-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2024-11-07 US disclosed
US-20240279215-A1 NAMPT MODULATORS CYTOKINETICS, INCORPORATED 2024-08-22 US disclosed
CN-117794918-A Substituted tetrahydrofuran analogues as sodium channel modulators 沃泰克斯药物股份有限公司 2024-03-29 CN disclosed
WO-2023177700-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2023-09-21 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279215-A1 NAMPT MODULATORS NAMPT, SIRT1, NNT P4HTM 1987/4885P4HA1 1342/4885MIF 2596/4885
US-20240368150-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER BICRA, BRD4, CNR1 P4HTM 2373/4885P4HA1 2118/4885MIF 4881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.